Back to search
FDAFDA · Food and drugs·Recall number D-0983-2017

Buprenorphine and Naloxone Sublingual Tablets, 2 mg/0.5 mg 30 tablets per bottle, Rx only, Distributed by: Teva Pharmaceuticals USA, Inc., North Wales, PA 19454, NDC 0093-5720-56

Published July 26, 2017 · Recall initiated: June 29, 2017

Summary

FDA records drug Class III recall D-0983-2017, published July 26, 2017 and initiated June 29, 2017. Recalling firm: Teva Pharmaceuticals USA; Status: Terminated; Reported quantity: 25264 bottles; Lot: Lot #: 30227613A, 30227614A, 30227615A, EXP 6/2017; 30228559A, 30228560A, EXP 9/2017; 3000123, EXP 7/2018. Class III means the product is not likely to cause adverse health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Failed Impurities/Degradation Specifications: out of specification test results for related compounds largest unknown impurity.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Teva Pharmaceuticals USA
Distributor
Nationwide in the USA
Lot
Lot #: 30227613A, 30227614A, 30227615A, EXP 6/2017; 30228559A, 30228560A, EXP 9/2017; 3000123, EXP 7/2018
Risk classification
Class III
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Buprenorphine and Naloxone Sublingual Tablets, 2 mg/0.5 mg 30 tablets per bottle, Rx only, Distributed by: Teva Pharmaceuticals USA, Inc., North Wales, PA 19454, NDC 0093-5720-56 recalled?

Yes. FDA published recall D-0983-2017 on July 26, 2017. Reported hazard: Failed Impurities/Degradation Specifications: out of specification test results for related compounds largest unknown impurity.

What should I do if I have this product?

Voluntary: Firm initiated · Letter